

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

We claim:

Claim 1. (Cancelled)

Claim 2. (Previously Presented) The method according to claim 14, wherein the growth-factor receptor is epidermal growth factor receptor (EGFR).

Claim 3. (Cancelled)

Claim 4. (Cancelled)

Claim 5. (Cancelled)

Claim 6. (Cancelled)

Claim 7. (Cancelled)

Claim 8. (Previously Presented) The method according to claim 14, comprising administering to said subject in need thereof a pharmaceutical composition which comprises said antibody and at least one pharmaceutically acceptable carrier, diluent or adjuvant.

Claim 9. (Cancelled)

Claim 10. (Previously Presented) The method according to claim 13, wherein the cancer is a human cancer.

Claim 11. (Withdrawn) A method for identifying and/or characterizing an inhibitor of processes selected from cell proliferation, cell migration, invasivity and anti-apoptosis in a disorder associated with increased G-protein mediated signal transduction, comprising: determining the effect of a test compound on the

transactivation of a growth-factor receptor of the EGFR family.

Claim 12. (Withdrawn) The method of claim 11, wherein the test compound is selected from low-molecular weight compounds, peptides and proteins, particularly antibodies or antibody fragments.

Claim 13. (Previously Presented) A method for the treatment of cell proliferation, cell migration, invasivity or anti-apoptosis in a cancer,

wherein said cancer is associated with increased G-protein mediated signal transduction and is at least one of colon cancer, kidney cancer, bladder cancer, prostate cancer, breast cancer, lung cancer or ovarian cancer,

comprising administering to a subject in need thereof an effective amount of an antibody which binds to pro-HB-EGF.

Claim 14. (Previously Presented) The method according to claim 13, wherein the antibody inhibits activation of a growth-factor receptor of the EGFR family.

Claim 15. (Previously Presented) The method according to claim 14, wherein the growth-factor receptor of the EGFR family is HER-2, HER-3 or HER-4.

Claim 16. (Currently Amended) The method according to claim 13, wherein the cancer is kidney ~~for the treatment of cell proliferation, cell migration, invasivity or anti-apoptosis in a cancer.~~

Claim 17. (Previously Presented) A method for the treatment of cell proliferation, cell migration, invasivity or anti-apoptosis in a cancer,

wherein said cancer is associated with increased G-protein mediated signal transduction and is at least one of colon cancer, kidney cancer, bladder cancer, prostate cancer, breast cancer, lung cancer or ovarian cancer,

comprising administering to a subject in need thereof an effective amount of a

composition which comprises an acceptable carrier, diluent or adjuvant and an antibody which binds to pro-HB-EGF.

Claim 18. (New) The method according to claim 17, wherein the cancer is kidney cancer.